May 9th 2025
Poor API quality may often lead to delays in production and a shortage of supply.
The evolution of therapeutic modalities drives the adoption of single-use technologies.
Manufacturing High-Potency Drugs Using Isolators
November 1st 2008The author discusses the key issues to consider when using isolators such as containment, protection of personnel, the efficiency of biodecontamination cycles, sterility assurance levels, barriers and their integrity, and environmental impact.
Zebrafish: a multifaceted approach for drug safety assessment
November 1st 2008Many compounds fail in preclinical development because of safety-related problems, but identifying 'predictable' safety or toxicity liabilities earlier in the process could lead to improved design and selection of compounds that are more likely to be approved.